Cytokeratin 7 is a Predictive Marker for Survival in Patients with Esophageal Squamous Cell Carcinoma
Cytokeratin 7 is a Predictive Marker for Survival in Patients with Esophageal Squamous Cell Carcinoma
复制标题
DOI：
10.1245/s10434-011-2175-4
复制
发表时间：
2012-06-01
影响因子：
3.7
通讯作者：
Yasui, Wataru
中科院分区：
文献类型：
--
作者：
Oue, Naohide;Noguchi, Tsuyoshi;Yasui, Wataru
诊断为II期和III期食管鳞状细胞癌（ESCC）的患者预后不一。这一群体将从能够识别辅助治疗有利个体的预后标记物的发现中获益良多。本研究的目的是探讨免疫组织化学检测的细胞角蛋白7 （CK7）表达对ESCC患者无病生存、总生存期（OS）或治疗结果的影响。对225例手术切除的0-III期ESCC进行CK7免疫组化分析。225例ESCC患者中，有20例（9%）CK7阳性。在0-III期ESCC患者中，CK7表达与OS有统计学意义相关，独立于临床协变量，包括肿瘤、淋巴结、转移系统分期。在II期和III期ESCC患者（= 124）中，CK7表达与较差的OS显著相关（= 0.0377）。此外，在未接受辅助化疗的II期和III期ESCC患者中（= 73），CK7表达与较差的OS显著相关（= 0.0003）。在接受辅助化疗的II期和III期ESCC患者中，CK7表达与治疗结果无关。在ck7阳性ESCC患者（= 16）中，接受辅助化疗对II期和III期ESCC患者更有利（= 0.0654）。免疫组织化学分析CK7将有助于识别高危患者。
Patients diagnosed with stage II and III esophageal squamous cell carcinoma (ESCC) have variable prognosis. This group would benefit greatly from the discovery of prognostic markers that are capable of identifying individuals for whom adjuvant treatment would be advantageous. The aim of this study was to investigate the impact of immunohistochemically detected cytokeratin 7 (CK7) expression on disease-free survival, overall survival (OS), or therapeutic outcome in patients with ESCC.Immunohistochemical analysis of CK7 was performed on 225 surgically resected specimens of stage 0-III ESCC.In total, 20 (9%) of 225 ESCC cases were positive for CK7. In stage 0-III ESCC patients, CK7 expression was statistically significantly associated with OS, independent of clinical covariates, including tumor, node, metastasis system stage. In stage II and III ESCC patients ( = 124), CK7 expression was significantly associated with poorer OS ( = 0.0377). Furthermore, in stage II and III ESCC patients who did not receive adjuvant chemotherapy ( = 73), CK7 expression was significantly associated with poorer OS ( = 0.0003). CK7 expression was not associated with therapeutic outcome in patients with stage II and III ESCC who received adjuvant chemotherapy. In patients with CK7-positive ESCC ( = 16), receipt of adjuvant chemotherapy tended to be beneficial for patients with stage II and III ESCC ( = 0.0654).Immunohistochemical analysis of CK7 will help to identify high-risk patients.